JP6480090B1 - 二本鎖rna高含有乳酸菌の製造方法及び該乳酸菌 - Google Patents
二本鎖rna高含有乳酸菌の製造方法及び該乳酸菌 Download PDFInfo
- Publication number
- JP6480090B1 JP6480090B1 JP2018544952A JP2018544952A JP6480090B1 JP 6480090 B1 JP6480090 B1 JP 6480090B1 JP 2018544952 A JP2018544952 A JP 2018544952A JP 2018544952 A JP2018544952 A JP 2018544952A JP 6480090 B1 JP6480090 B1 JP 6480090B1
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- double
- stranded rna
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 460
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 230
- 239000004310 lactic acid Substances 0.000 title claims abstract description 230
- 241000894006 Bacteria Species 0.000 title claims abstract description 226
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 147
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims abstract description 143
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 238000005273 aeration Methods 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims description 71
- 230000007423 decrease Effects 0.000 claims description 21
- 241000186660 Lactobacillus Species 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 18
- 229940039696 lactobacillus Drugs 0.000 claims description 18
- 230000000813 microbial effect Effects 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 14
- 241000192001 Pediococcus Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 9
- 241000500334 Tetragenococcus Species 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 241000192132 Leuconostoc Species 0.000 claims description 7
- 241000194036 Lactococcus Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 description 43
- 239000000243 solution Substances 0.000 description 32
- 102000016943 Muramidase Human genes 0.000 description 11
- 108010014251 Muramidase Proteins 0.000 description 11
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 11
- 235000010335 lysozyme Nutrition 0.000 description 11
- 239000004325 lysozyme Substances 0.000 description 11
- 229960000274 lysozyme Drugs 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 230000003308 immunostimulating effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000191998 Pediococcus acidilactici Species 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 210000003850 cellular structure Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000005007 innate immune system Anatomy 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000006872 mrs medium Substances 0.000 description 6
- 235000019833 protease Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000002924 anti-infective effect Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 244000057717 Streptococcus lactis Species 0.000 description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 3
- 241000186612 Lactobacillus sakei Species 0.000 description 3
- 241000192129 Leuconostoc lactis Species 0.000 description 3
- 241000191996 Pediococcus pentosaceus Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/157—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(1)乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下の培養に供することにより、二本鎖RNA含有乳酸菌を得る工程を含む、二本鎖RNA含有乳酸菌の製造方法。
(2)乳酸菌を、通気条件および至適温度より低温度条件下の培養に供することにより、二本鎖RNA含有乳酸菌を得る工程を含む、(1)に記載の二本鎖RNA含有乳酸菌の製造方法。
(3)二本鎖RNA含有乳酸菌における二本鎖RNAの含有量が、至適温度かつ非通気条件下で同一の培養時間で同一の菌株を培養したときの二本鎖RNAの含有量と比べて、2.0倍以上である、(1)または(2)に記載の製造方法。
(4)二本鎖RNA含有乳酸菌における二本鎖RNAの含有量が、乾燥菌体1mgあたり20ng以上である、(1)〜(3)のいずれか1に記載の製造方法。
(5)前記乳酸菌は、ペディオコッカス(Pediococcus)属乳酸菌、ラクトコッカス(Lactococcus)属乳酸菌、ラクトバチルス(Lactobacillus)属乳酸菌、ストレプトコッカス(Streptococcus)属乳酸菌、ロイコノストック(Leuconostoc)属乳酸菌及びテトラジェノコッカス(Tetragenococcus)属乳酸菌からなる群から選ばれる少なくとも1である、(1)〜(4)のいずれか1に記載の製造方法。
(6)乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下の培養に供することにより、該乳酸菌の二本鎖RNAの含有量の低下を抑制する工程を含む、乳酸菌の二本鎖RNAの含有量の低下を抑制する方法。
(7)複数の乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下の培養に供することにより、二本鎖RNA含有乳酸菌をスクリーニングする工程を含む、二本鎖RNA含有乳酸菌のスクリーニング方法。
(8)二本鎖RNAの含有量が、至適温度かつ非通気条件下で同一の培養時間で同一の菌株を培養したときの二本鎖RNAの含有量と比べて、2.0倍以上である、二本鎖RNA含有乳酸菌。
(9)二本鎖RNAの含有量が、乾燥菌体1mgあたり20ng以上である、二本鎖RNA含有乳酸菌。
(10)前記乳酸菌は、ペディオコッカス(Pediococcus)属乳酸菌、ラクトコッカス(Lactococcus)属乳酸菌、ラクトバチルス(Lactobacillus)属乳酸菌、ストレプトコッカス(Streptococcus)属乳酸菌、ロイコノストック(Leuconostoc)属乳酸菌及びテトラジェノコッカス(Tetragenococcus)属乳酸菌からなる群から選ばれる少なくとも1である、(8)または(9)に記載の乳酸菌。
(11)(8)〜(10)のいずれか1に記載の乳酸菌を含有する組成物。
(12)前記組成物は、飲食品用組成物、飲食品原料用組成物、飼料用組成物及び飼料原料用組成物からなる群から選ばれる1である、(11)に記載の組成物。
乳酸菌を通気条件下で培養した際の二本鎖RNA量を評価した。
ペディオコッカス属に属する乳酸菌を種々の培養温度により培養した際の二本鎖RNA量を評価した。
ペディオコッカス属に属する乳酸菌を至適温度より低温度条件かつ通気条件下で培養した際の二本鎖RNA量を評価した。
乳酸菌を通気条件下で培養した際の二本鎖RNA量を評価した。
Claims (12)
- 乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下で該乳酸菌の増殖速度が低下する前の時間での培養に供することにより、二本鎖RNA含有乳酸菌を得る工程を含む、二本鎖RNA含有乳酸菌の製造方法。
- 乳酸菌を、通気条件および至適温度より低温度条件下で該乳酸菌の増殖速度が低下する前の時間での培養に供することにより、二本鎖RNA含有乳酸菌を得る工程を含む、請求項1に記載の二本鎖RNA含有乳酸菌の製造方法。
- 二本鎖RNA含有乳酸菌における二本鎖RNAの含有量が、至適温度かつ非通気条件下で同一の培養時間で同一の菌株を培養したときの二本鎖RNAの含有量と比べて、2.0倍以上である、請求項1または2に記載の製造方法。
- 二本鎖RNA含有乳酸菌における二本鎖RNAの含有量が、乾燥菌体1mgあたり20ng以上である、請求項1〜3のいずれか1項に記載の製造方法。
- 前記乳酸菌は、ペディオコッカス(Pediococcus)属乳酸菌、ラクトコッカス(Lactococcus)属乳酸菌、ラクトバチルス(Lactobacillus)属乳酸菌、ストレプトコッカス(Streptococcus)属乳酸菌、ロイコノストック(Leuconostoc)属乳酸菌及びテトラジェノコッカス(Tetragenococcus)属乳酸菌からなる群から選ばれる少なくとも1である、請求項1〜4のいずれか1項に記載の製造方法。
- 乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下で該乳酸菌の増殖速度が低下する前の時間での培養に供することにより、該乳酸菌の二本鎖RNAの含有量の低下を抑制する工程を含む、乳酸菌の二本鎖RNAの含有量の低下を抑制する方法。
- 複数の乳酸菌を、通気条件および至適温度より低温度条件の少なくとも一方の条件下で該乳酸菌の増殖速度が低下する前の時間での培養に供することにより、二本鎖RNA含有乳酸菌をスクリーニングする工程を含む、二本鎖RNA含有乳酸菌のスクリーニング方法。
- 二本鎖RNAの含有量が、至適温度かつ非通気条件下で同一の培養時間で同一の菌株を培養したときの二本鎖RNAの含有量と比べて、2.0倍以上である、二本鎖RNA含有乳酸菌(ただし、ラクトバチルス(Lactobacillus)属乳酸菌を除く。)。
- 二本鎖RNAの含有量が、乾燥菌体1mgあたり20ng以上である、二本鎖RNA含有乳酸菌(ただし、ラクトバチルス(Lactobacillus)属乳酸菌を除く。)。
- 前記乳酸菌は、ペディオコッカス(Pediococcus)属乳酸菌、ラクトコッカス(Lactococcus)属乳酸菌、ストレプトコッカス(Streptococcus)属乳酸菌、ロイコノストック(Leuconostoc)属乳酸菌及びテトラジェノコッカス(Tetragenococcus)属乳酸菌からなる群から選ばれる少なくとも1である、請求項8または9に記載の乳酸菌。
- 請求項8〜10のいずれか1項に記載の乳酸菌を含有する組成物。
- 前記組成物は、飲食品用組成物、飲食品原料用組成物、飼料用組成物及び飼料原料用組成物からなる群から選ばれる1種の組成物である、請求項11に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017095947 | 2017-05-12 | ||
JP2017095947 | 2017-05-12 | ||
PCT/JP2018/018392 WO2018207924A1 (ja) | 2017-05-12 | 2018-05-11 | 二本鎖rna高含有乳酸菌の製造方法及び該乳酸菌 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6480090B1 true JP6480090B1 (ja) | 2019-03-06 |
JPWO2018207924A1 JPWO2018207924A1 (ja) | 2019-06-27 |
Family
ID=64104608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018544952A Active JP6480090B1 (ja) | 2017-05-12 | 2018-05-11 | 二本鎖rna高含有乳酸菌の製造方法及び該乳酸菌 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11518976B2 (ja) |
EP (1) | EP3623464A4 (ja) |
JP (1) | JP6480090B1 (ja) |
CN (1) | CN110651035B (ja) |
WO (1) | WO2018207924A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09238647A (ja) * | 1996-03-08 | 1997-09-16 | Yakult Honsha Co Ltd | がん予防食品 |
JPH10139674A (ja) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | インターロイキン12産生促進剤 |
WO2003082027A1 (fr) * | 2002-03-29 | 2003-10-09 | Frente International Co., Ltd. | Preparations cellulaires vitales et aliments contenant une bacterie lactique comme principe actif |
WO2009005123A1 (ja) * | 2007-07-03 | 2009-01-08 | Kikkoman Corporation | インターフェロンβ産生促進剤及びその製造法 |
WO2009005124A1 (ja) * | 2007-07-04 | 2009-01-08 | Kikkoman Corporation | 乳酸菌由来の2本鎖rna |
JP2014140330A (ja) * | 2013-01-24 | 2014-08-07 | Sapporo Breweries Ltd | 乳酒の製造方法及び乳酒 |
JP2015092841A (ja) * | 2013-11-11 | 2015-05-18 | キッコーマン株式会社 | 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312322B2 (ja) | 1972-05-16 | 1978-04-28 | ||
JP2008301812A (ja) * | 2007-05-10 | 2008-12-18 | Okayama Univ | 乳酸菌において二本鎖rnaを生成するキット及びその利用 |
WO2010050109A1 (ja) * | 2008-10-30 | 2010-05-06 | 国立大学法人岡山大学 | 乳酸菌により二本鎖rnaを生成するキット及びその利用 |
JP2010252641A (ja) * | 2009-04-22 | 2010-11-11 | Mitsubishi Rayon Co Ltd | 乳酸菌由来多糖類の製造方法 |
JP2014050325A (ja) * | 2012-09-05 | 2014-03-20 | Nippon Meat Packers Inc | 乳酸菌の低温増殖性改善方法 |
JP6588313B2 (ja) | 2015-11-20 | 2019-10-09 | 三協立山株式会社 | 建具 |
-
2018
- 2018-05-11 CN CN201880031057.4A patent/CN110651035B/zh active Active
- 2018-05-11 WO PCT/JP2018/018392 patent/WO2018207924A1/ja active Application Filing
- 2018-05-11 JP JP2018544952A patent/JP6480090B1/ja active Active
- 2018-05-11 EP EP18798729.2A patent/EP3623464A4/en active Pending
- 2018-05-11 US US16/612,103 patent/US11518976B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09238647A (ja) * | 1996-03-08 | 1997-09-16 | Yakult Honsha Co Ltd | がん予防食品 |
JPH10139674A (ja) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | インターロイキン12産生促進剤 |
WO2003082027A1 (fr) * | 2002-03-29 | 2003-10-09 | Frente International Co., Ltd. | Preparations cellulaires vitales et aliments contenant une bacterie lactique comme principe actif |
WO2009005123A1 (ja) * | 2007-07-03 | 2009-01-08 | Kikkoman Corporation | インターフェロンβ産生促進剤及びその製造法 |
WO2009005124A1 (ja) * | 2007-07-04 | 2009-01-08 | Kikkoman Corporation | 乳酸菌由来の2本鎖rna |
JP2014140330A (ja) * | 2013-01-24 | 2014-08-07 | Sapporo Breweries Ltd | 乳酒の製造方法及び乳酒 |
JP2015092841A (ja) * | 2013-11-11 | 2015-05-18 | キッコーマン株式会社 | 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物 |
Non-Patent Citations (1)
Title |
---|
IMMUNITY, 2013, VOL.38, P.1187-1197, JPN6018028174, ISSN: 0003921277 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2018207924A1 (ja) | 2019-06-27 |
CN110651035B (zh) | 2024-03-19 |
WO2018207924A1 (ja) | 2018-11-15 |
EP3623464A4 (en) | 2020-07-08 |
EP3623464A1 (en) | 2020-03-18 |
US20200115673A1 (en) | 2020-04-16 |
US11518976B2 (en) | 2022-12-06 |
CN110651035A (zh) | 2020-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8557233B2 (en) | Probiotic bifidobacterium strains | |
KR101355770B1 (ko) | 면역조절 활성이 높은 유산균의 배양법 | |
US20140328879A1 (en) | Probiotic bifidobacterium strains | |
CN108135946A (zh) | 长双歧杆菌 | |
ES2407150T3 (es) | Bacteria ácido láctica novedosa con actividad anti-alérgica, agente anti-alérgico, alimento y composición farmacéutica que comprenden, cada uno de ellos, la bacteria ácido láctica, y proceso para la producción del agente anti-alérgico | |
JP5082048B2 (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
KR102224072B1 (ko) | 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도 | |
JP6821643B2 (ja) | 免疫疾患予防剤 | |
JP6796299B2 (ja) | 免疫賦活用組成物及びサイトカイン産生促進用組成物 | |
WO2021157435A1 (ja) | 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料 | |
JP5610472B2 (ja) | 新規乳酸菌及び新規乳酸菌含有組成物 | |
JP6491422B2 (ja) | 免疫疾患予防剤 | |
Kumar et al. | Bifidobacteria for life betterment | |
JP2022523701A (ja) | 内臓痛の予防および/または処置のためのラクトコッカス・ラクティス株 | |
JP6480090B1 (ja) | 二本鎖rna高含有乳酸菌の製造方法及び該乳酸菌 | |
Gill | Lactic acid bacteria as probiotics: Current status and future prospects | |
WO2021157434A1 (ja) | 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料 | |
JP2023023981A (ja) | 生体内のIgAとIFN-γ産生を促進する乳酸菌製剤及び経口組成物 | |
JP6704990B2 (ja) | インターフェロンλ産生促進用組成物及びその製造方法 | |
JP2021123561A (ja) | 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料 | |
JP2021123562A (ja) | 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料 | |
JP2017197486A (ja) | インターフェロンλ誘導剤 | |
JP2006067881A (ja) | 新規乳酸菌と乳酸菌製剤 | |
JP2009112232A (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
JP6836298B1 (ja) | 乳酸菌及び納豆菌を含む組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180824 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180824 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180824 |
|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181011 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20181114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6480090 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |